The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: A randomized controlled trial-Reference-Cited by-同舟云学术

The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: A randomized controlled trial

Published:2012-07 Issue:34 Volume:30 Page:5132-5140
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Dagan Ron,Givon-Lavi Noga,Porat Nurith,Greenberg David

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference33 articles.

1. Annex I. Summary of product characteristics. Prevenar suspension for injection, pneumococcal saccharide conjugated vaccine adsorbed;EMEA,2012

2. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine—a randomized controlled trial;Givon-Lavi;Pediatr. Infect Dis J,2010

3. Pneumococcal polysaccharide-protein (CRM197) conjugate vaccines, 7- or 9-valent, in the 2+1 schedule;Fritzell;Expert Rev Vaccines,2011

4. Reduction of carriage and transmission of Streptococcus pneumoniae: the beneficial side effect of pneumococcal conjugate vaccine;Azzari;Clin Infect Dis,2008

5. (PneumoCarr) atPCG. Nasopharyngeal colonization: a target for pneumococcal vaccination;Kayhty;Expert Rev Vaccines,2006

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen;Expert Review of Vaccines;2024-04-09

2. Dynamics of invasive pneumococcal disease in infants < 2 years old following PCV7/13 implementation using two infant and a booster dose schedule: evidence for indirect protection of young infants, Israel, 2004 to 2019;Eurosurveillance;2023-06-22

3. Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021;EUROSURVEILLANCE;2023

4. Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines;Plotkin's Vaccines;2023

5. Nasopharyngeal carriage, serotype pattern and antimicrobial non-susceptibilities of Streptococcus pneumoniae among healthy children in the 13-valent pneumococcal conjugate vaccine era in Barbados, one of the Caribbean countries;Vacunas (English Edition);2021-09